Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
RELISTOR® Injection Protected from Generic Competition Until 2024
LAVAL, Quebec, May 2, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone bromide) Injection. The ruling prevents generic competition in the United States until 2024.
Plaintiffs in the case, including Progenics Pharmaceuticals, Salix Pharmaceuticals, Inc., Valeant and Wyeth LLC, had filed a motion for summary judgment on challenges to the validity of Claim 8 of U.S. Patent No. 8,552,025, which protects the formulation of RELISTOR® Injection.
Defendants in the case, which include Mylan Inc., Mylan Laboratories LTD., Mylan Pharmaceuticals, Inc. and Actavis LLC., had previously stipulated to infringement of Claim 8 and have no remaining invalidity defenses.
In the upcoming trial on June 4, the court will decide the infringement and validity of other patents that could prevent generic RELISTOR® vials until 2029 and generic RELISTOR® syringes until 2030.
Valeant will continue to vigorously defend its intellectual property in these and other claims.
